Esineb vahemikus 0,3 kuni 3 müokardiidi juhtumit 100000 isiku kohta. Seega tõenäosus on väike, kuid sihtgrupp, kellel see esineb, on selgelt tuvastatav.
Selles osas vajab mRNA vaktsiin veel tuunimist, sest vaktsineerides südameprobleemidega patsiente Covidi vastu mitte mRNA vaktsiiniga müokardiidi kordumist ei täheldatud.
https://www.mdpi.com/2076-393X/10/10/1772
Since the introduction of mRNA COVID-19 vaccines, uncommon reports of post-vaccination myocarditis have surfaced, contributing to further concerns over their safety [4]. As of March 2022, more than 18,000 myocarditis and pericarditis events post-COVID-19 mRNA vaccinations in the UK, USA, and EU/EAA population have been submitted to the respective regulatory bodies [5]. Most cases occurred within six weeks of receiving mRNA vaccines, more commonly after the second dose, and predominantly affected males aged 30 and below [15]. There is no existing data that describe myocarditis in ARD patients post-mRNA COVID-19 vaccination or COVID-19 infection. In a recently published nationwide population-based study in Singapore, 25 cases of myocarditis (12 confirmed, 13 probable) were reported against a background of 7,183,889 doses of COVID-19 mRNA vaccines administered [16]. This translates to an overall incidence of 0.35 cases per 100,000 vaccine doses, with the highest incidence in males aged 12–19 years, followed by those aged 20–29 years (3.72 and 0.98 per 100,000 vaccine doses, respectively) [16]. Most cases occurred after the second dose, were mild, and responded well to treatment (details on treatment not available). No myocarditis was reported in females below the age of 40 or for both genders above 60 years of age. The US CDC reported an overall similar rate of myocarditis of 0.35 per 100,000 with the second dose of mRNA COVID-19 vaccine predominantly affecting males aged 18–29 years at 2.43 cases per 100,000 doses administered [17]. An Israeli nationwide study reported about 3 excess myocarditis cases per 100,000 persons following mRNA COVID-19 vaccination that mainly affected younger males (median age 25 years (IQR 20–34), 90.9% males) as observed in other studies [3]. The reported cases were mostly mild and, if required, treated with colchicine, non-steroidal anti-inflammatory drugs, and glucocorticoids; those with left ventricular dysfunction, heart failure, or hemodynamic instability were treated with IVIg along with other cardiac or circulatory support measures [18]. Overall, the prognosis is good as these cases are usually self-limiting [18]. Most patients had resolutions of signs and symptoms with improvements in diagnostic markers and imaging with or without treatment [18].
Samuti käivitavad mRNA vaktsiinid autoimmuunseid haigusi nagu näiteks Guillain-Barre sündroom, reuma jne.
https://pubmed.ncbi.nlm.nih.gov/34957554/
Seega võib lubatud antivakserite hulgaks lugeda 3 inimest 100000 kohta ehk Eestis kokku ~40 inimest. FB järgi otsustades neid vist palju rohkem pole ka...
Vihkad Eestit? Vali Reformierakond.